Adverse Events Reported by Patients With Cancer After Administration of a 2-Dose mRNA COVID-19 Vaccine
Rebecca M. Shulman, Eric M. Horwitz(Fox Chase Cancer Center), Pritish Iyer(Palmetto Hematology Oncology), Peter D. Whooley(Beth Israel Deaconess Medical Center), Glenn F. Rall(Institute of Cancer Research), Melissa McShane(Palmetto Hematology Oncology), Marshall Strother(Anesthesiology and Surgical Oncology Research Group), Lauren Laderman(Temple University), David Y.T. Chen(Anesthesiology and Surgical Oncology Research Group), Daniel M. Geynisman(Fox Chase Cancer Center), Robert G. Uzzo(American Urological Association), Kevin Zarrabi(Stony Brook University), Eric A. Ross(Fox Chase Cancer Center), H.N. Yankey, N. Burbure, Erica Huelsmann(Palmetto Hematology Oncology), Timothy P. Dougherty, David S. Weinberg(Fox Chase Cancer Center), Samuel Reiss(Temple University), James Helstrom(Anesthesiology and Surgical Oncology Research Group), Sunil Adige(Palmetto Hematology Oncology), Anthony J. Olszanski(Fox Chase Cancer Center), Charles T. Lee, Riley Williams(Institute of Cancer Research), Carolyn Y. Fang(Fox Chase Cancer Center), Brinda Gupta(Georgetown University), Richard I. Fisher(University of Rochester), Karen Ruth(Fox Chase Cancer Center), Julie Giurintano(Temple University), Julia Judd(Palmetto Hematology Oncology), Michael J. Hall(Fox Chase Cancer Center)
Cited by 23
Related Papers
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k
Oncogenically active MYD88 mutations in human lymphoma
|Nature|2010|1.5k